PL3216793T3 - Związki triazynowe jako inhibitory kinazy p13 i mtor - Google Patents

Związki triazynowe jako inhibitory kinazy p13 i mtor

Info

Publication number: PL3216793T3
Authority: PL; Poland
Prior art keywords: kinase; mtor inhibitors; triazine compounds; triazine; mtor
Prior art date: 2008-05-23

Application number

PL17162947T

Other languages

English (en)

Inventor

Aranapakam M. Venkatesan

Zecheng Chen

Christoph M. Dehnhardt

Osvaldo Dos Santos

Efren Guillermo Delos Santos

Arie Zask

Jeroen C. Verheijen

Joshua Aaron Kaplan

David J. Richard

Semiramis Ayral-Kaloustian

Tarek S. Mansour

Ariamala Gopalsamy

Kevin J. Curran

Mengxiao Shi

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-23

Filing date

2009-05-21

Publication date

2019-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3216793(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-21 Application filed by Wyeth Llc filed Critical Wyeth Llc

2019-09-30 Publication of PL3216793T3 publication Critical patent/PL3216793T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17162947T 2008-05-23 2009-05-21 Związki triazynowe jako inhibitory kinazy p13 i mtor PL3216793T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US5566108P	2008-05-23	2008-05-23
EP09751541.5A EP2294072B1 (en)	2008-05-23	2009-05-21	Triazine compounds as p13 kinase and mtor inhibitors
PCT/US2009/044774 WO2009143313A1 (en)	2008-05-23	2009-05-21	Triazine compounds as p13 kinase and mtor inhibitors
EP17162947.0A EP3216793B1 (en)	2008-05-23	2009-05-21	Triazine compounds as p13 kinase and mtor inhibitors

Publications (1)

Publication Number	Publication Date
PL3216793T3 true PL3216793T3 (pl)	2019-09-30

Family

ID=40911929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17162947T PL3216793T3 (pl)	2008-05-23	2009-05-21	Związki triazynowe jako inhibitory kinazy p13 i mtor

Country Status (43)

Country	Link
US (8)	US20090304692A1 (pl)
EP (3)	EP2300483A1 (pl)
JP (2)	JP4948677B2 (pl)
KR (1)	KR101331341B1 (pl)
CN (2)	CN102036995B (pl)
AP (2)	AP2775A (pl)
AR (2)	AR071909A1 (pl)
AU (2)	AU2009248993C1 (pl)
BR (1)	BRPI0912294B8 (pl)
CA (2)	CA2721692C (pl)
CL (2)	CL2009001274A1 (pl)
CO (1)	CO6311070A2 (pl)
CR (1)	CR11757A (pl)
CU (1)	CU23887B1 (pl)
CY (2)	CY1118879T1 (pl)
DK (2)	DK3216793T3 (pl)
DO (1)	DOP2010000315A (pl)
EA (1)	EA020317B1 (pl)
EC (2)	ECSP10010624A (pl)
ES (2)	ES2625467T3 (pl)
GE (1)	GEP20125589B (pl)
HR (2)	HRP20170637T1 (pl)
HU (1)	HUE043331T2 (pl)
IL (2)	IL209061A0 (pl)
LT (2)	LT3216793T (pl)
MA (1)	MA32319B1 (pl)
ME (1)	ME01111B (pl)
MX (1)	MX2010012808A (pl)
MY (1)	MY155653A (pl)
NI (1)	NI201000198A (pl)
NZ (1)	NZ588526A (pl)
PA (2)	PA8828201A1 (pl)
PE (2)	PE20091943A1 (pl)
PL (1)	PL3216793T3 (pl)
PT (2)	PT3216793T (pl)
RS (2)	RS58724B1 (pl)
SA (1)	SA109300314B1 (pl)
SI (2)	SI3216793T1 (pl)
TR (1)	TR201906123T4 (pl)
TW (2)	TW201008949A (pl)
UA (1)	UA99361C2 (pl)
WO (2)	WO2009143317A1 (pl)
ZA (1)	ZA201007204B (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10022381B2 (en) *	2008-05-23	2018-07-17	Pfizer Inc.	Triazine compounds as PI3 kinase and mTOR inhibitors
ES2554513T3 (es)	2008-05-23	2015-12-21	Novartis Ag	Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
EP2300483A1 (en) *	2008-05-23	2011-03-30	Wyeth LLC	Triazine compounds as p13 kinase and mtor inhibitors
GB2465405A (en) *	2008-11-10	2010-05-19	Univ Basel	Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010096619A1 (en) *	2009-02-23	2010-08-26	Wyeth Llc	Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
JP5766177B2 (ja)	2009-03-27	2015-08-19	ベトディーシー，インコーポレイテッド	ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
UY32582A (es)	2009-04-28	2010-11-30	Amgen Inc	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2532659A1 (en)	2009-07-07	2012-12-12	Pathway Therapeutics, Inc.	Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CN102470127A (zh) *	2009-08-19	2012-05-23	埃姆比特生物科学公司	联芳基化合物和其使用方法
WO2011087812A1 (en) *	2009-12-21	2011-07-21	Vanderbilt University	Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
WO2011109833A2 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
GB201004200D0 (en) *	2010-03-15	2010-04-28	Univ Basel	Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9481670B2 (en) *	2011-01-25	2016-11-01	Sphaera Pharma Pte. Ltd.	Triazine compounds
JP2014505076A (ja) *	2011-01-27	2014-02-27	ザトラスティーズオブプリンストンユニバーシティ	抗ウイルス剤としてのｍＴＯＲキナーゼの阻害剤
US8653089B2 (en) *	2011-02-09	2014-02-18	F. Hoffmann-La Roche Ag	Heterocyclic compounds and methods of use
JP6042406B2 (ja)	2011-03-28	2016-12-14	メイプハルマ，インコーポレーテッド	（α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
CN102250065B (zh) *	2011-05-20	2015-05-13	浙江海正药业股份有限公司	取代的三嗪苯脲衍生物及其用途
CN102887867B (zh) *	2011-07-21	2015-04-15	中国科学院上海药物研究所	一类三嗪类化合物、该化合物的制备方法及其用途
US9175011B2 (en)	2011-09-21	2015-11-03	Cellzone Limited	Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
CN103946222B (zh)	2011-10-07	2016-12-28	塞尔佐姆有限公司	作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物
CN102659765B (zh) *	2011-12-31	2014-09-10	沈阳药科大学	嘧啶及三嗪类化合物的制备方法和应用
KR20160027218A (ko)	2012-05-23	2016-03-09	에프. 호프만-라 로슈 아게	내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
WO2014005182A1 (en) *	2012-07-04	2014-01-09	Monash University	Phosphoinositide 3-kinase (pi3k) inhibitors
US9630958B2 (en)	2012-07-23	2017-04-25	Sphaera Pharma Pte. Ltd.	Triazine compounds
GB201309807D0 (en)	2013-05-31	2013-07-17	Pharma Mar Sau	Antibody drug conjugates
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
MX378984B (es) *	2014-03-14	2025-03-11	Pfizer	Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.
CA2998647A1 (en) *	2014-10-03	2016-04-07	The Royal Institution For The Advancement Of Learning/Mcgill University	Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
US10617670B2 (en) *	2014-10-10	2020-04-14	Pfizer Inc.	Synergistic auristatin combinations
JP6695875B2 (ja)	2014-11-20	2020-05-20	カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ	抗がん剤としての新規な１，３，５−トリアジン系ｐｉ３ｋ阻害剤及びその製造方法
US10172942B2 (en)	2014-12-17	2019-01-08	Pfizer Inc.	Formulations of a PI3K/mTor-inhibitor for intravenous administration
CN104725361B (zh) *	2015-04-09	2017-05-31	江苏富比亚化学品有限公司	一种受阻胺类光稳定剂3346的制备方法
EP3456712B1 (en) *	2016-05-12	2022-04-20	Nanjing Shiqi Pharmaceutical Co. Ltd.	Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
RU2765868C2 (ru) *	2016-05-18	2022-02-04	Торкур АГ	Лечение неврологических расстройств
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام
IT201700047189A1 (it) *	2017-05-02	2018-11-02	Fondazione St Italiano Tecnologia	Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
AU2018271862B2 (en)	2017-05-23	2022-12-15	Mei Pharma, Inc.	Combination therapy
JP2020531414A (ja)	2017-08-14	2020-11-05	エムイーアイファーマ，インク．	併用療法
ES2895370T3 (es)	2017-08-25	2022-02-21	Pfizer	Formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
CN108191837A (zh) *	2018-01-10	2018-06-22	贵州医科大学	PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
KR102022323B1 (ko) *	2018-03-30	2019-09-18	정하윤	트리아진 화합물 및 이의 용도
NZ805649A (en) *	2018-06-07	2024-11-29	Pfizer	Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
SG11202012447YA (en)	2018-06-15	2021-01-28	Navitor Pharm Inc	Rapamycin analogs and uses thereof
BR112021011894A2 (pt)	2018-12-21	2021-09-08	Daiichi Sankyo Company, Limited	Composição farmacêutica
CN109942562B (zh) *	2019-02-27	2022-02-08	江西科技师范大学	含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用
TW202134234A (zh)	2019-12-05	2021-09-16	美商奈維特製藥公司	雷帕黴素類似物及其用途
BR112022020142A2 (pt) *	2020-04-07	2022-11-22	Mei Pharma Inc	Preparação de um 1,3,5-triazinil benzimidazol
JP2024504378A (ja) *	2021-01-25	2024-01-31	アトスセラピューティクス，インコーポレイテッド	トリアジン化合物ならびにこれを作製する方法および使用する方法
KR20220138575A (ko)	2021-04-06	2022-10-13	부산대학교병원	전좌 신장암 치료 또는 예방용 약물 스크리닝 방법
CN113200969B (zh) *	2021-05-19	2022-11-25	中国药科大学	一种PI3Kα选择性抑制剂及其制备方法和应用
TW202320795A (zh)	2021-07-26	2023-06-01	美商凱爾科迪股份有限公司	使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
CN115109049B (zh) *	2022-08-12	2023-08-15	江西科技师范大学	含芳基脲结构的三嗪类化合物及其应用
CN115557908B (zh) *	2022-09-28	2024-10-15	九江学院	一种含硫连接键的三嗪类衍生物及其合成方法、用途
CN116102545B (zh) *	2023-02-01	2025-03-25	贵州医科大学	一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
CN116239580B (zh) *	2023-03-06	2025-05-23	中国药科大学	三嗪类化合物及其制备方法、药物组合物和应用
WO2025116280A1 (ko) *	2023-11-29	2025-06-05	주식회사 펩토이드	새로운 대칭형 플루오로트리아진 화합물 및 이들의 의학적 또는 생물학적 용도
WO2025128712A1 (en)	2023-12-12	2025-06-19	Celcuity Inc.	Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
CN120004875A (zh) *	2025-04-22	2025-05-16	中国药科大学	靶向降解磷脂酰肌醇3-激酶的化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2297326C (en) *	1997-07-24	2007-03-20	Zenyaku Kogyo Kabushiki Kaisha	Heterocyclic compound and antitumor agent containing the same as active component
DK1037886T3 (da) *	1997-12-12	2003-08-25	Abbott Lab	Triazin angiogeneseinhibitorer
US7071189B2 (en)	2001-04-27	2006-07-04	Zenyaku Kogyo Kabushiki Kaisha	Heterocyclic compound and antitumor agent containing the same as active ingredient
GB0512324D0 (en) *	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
MX2007010404A (es)	2005-02-25	2008-01-11	Kudos Pharm Ltd	Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
CA2660758A1 (en) *	2006-08-24	2008-02-27	Astrazeneca Ab	Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2300483A1 (en) *	2008-05-23	2011-03-30	Wyeth LLC	Triazine compounds as p13 kinase and mtor inhibitors

2009
- 2009-05-21 EP EP09751545A patent/EP2300483A1/en not_active Withdrawn
- 2009-05-21 SI SI200931969T patent/SI3216793T1/sl unknown
- 2009-05-21 UA UAA201013896A patent/UA99361C2/uk unknown
- 2009-05-21 TR TR2019/06123T patent/TR201906123T4/tr unknown
- 2009-05-21 MY MYPI2010005448A patent/MY155653A/en unknown
- 2009-05-21 PT PT17162947T patent/PT3216793T/pt unknown
- 2009-05-21 KR KR1020107026145A patent/KR101331341B1/ko active Active
- 2009-05-21 DK DK17162947.0T patent/DK3216793T3/da active
- 2009-05-21 LT LTEP17162947.0T patent/LT3216793T/lt unknown
- 2009-05-21 AU AU2009248993A patent/AU2009248993C1/en active Active
- 2009-05-21 BR BRPI0912294A patent/BRPI0912294B8/pt active IP Right Grant
- 2009-05-21 RS RS20190552A patent/RS58724B1/sr unknown
- 2009-05-21 PL PL17162947T patent/PL3216793T3/pl unknown
- 2009-05-21 MX MX2010012808A patent/MX2010012808A/es active IP Right Grant
- 2009-05-21 NZ NZ588526A patent/NZ588526A/xx unknown
- 2009-05-21 ES ES09751541.5T patent/ES2625467T3/es active Active
- 2009-05-21 HR HRP20170637TT patent/HRP20170637T1/hr unknown
- 2009-05-21 EA EA201071232A patent/EA020317B1/ru unknown
- 2009-05-21 AP AP2010005453A patent/AP2775A/xx active
- 2009-05-21 AP AP2010005452A patent/AP2010005452A0/xx unknown
- 2009-05-21 GE GEAP200912011A patent/GEP20125589B/en unknown
- 2009-05-21 EP EP09751541.5A patent/EP2294072B1/en active Active
- 2009-05-21 RS RS20170476A patent/RS55960B1/sr unknown
- 2009-05-21 CN CN200980118848.1A patent/CN102036995B/zh active Active
- 2009-05-21 LT LTEP09751541.5T patent/LT2294072T/lt unknown
- 2009-05-21 CA CA2721692A patent/CA2721692C/en active Active
- 2009-05-21 CA CA2721710A patent/CA2721710A1/en not_active Abandoned
- 2009-05-21 SI SI200931648A patent/SI2294072T1/sl unknown
- 2009-05-21 CN CN201410412345.8A patent/CN104230831B/zh active Active
- 2009-05-21 ME MEP-2010-188A patent/ME01111B/me unknown
- 2009-05-21 WO PCT/US2009/044784 patent/WO2009143317A1/en not_active Ceased
- 2009-05-21 DK DK09751541.5T patent/DK2294072T3/en active
- 2009-05-21 JP JP2011510697A patent/JP4948677B2/ja not_active Expired - Fee Related
- 2009-05-21 WO PCT/US2009/044774 patent/WO2009143313A1/en not_active Ceased
- 2009-05-21 JP JP2011510698A patent/JP2011520979A/ja not_active Withdrawn
- 2009-05-21 PT PT97515415T patent/PT2294072T/pt unknown
- 2009-05-21 ES ES17162947T patent/ES2728163T3/es active Active
- 2009-05-21 AU AU2009248997A patent/AU2009248997A1/en not_active Abandoned
- 2009-05-21 HU HUE17162947A patent/HUE043331T2/hu unknown
- 2009-05-21 EP EP17162947.0A patent/EP3216793B1/en active Active
- 2009-05-22 CL CL2009001274A patent/CL2009001274A1/es unknown
- 2009-05-22 US US12/470,525 patent/US20090304692A1/en not_active Abandoned
- 2009-05-22 CL CL2009001273A patent/CL2009001273A1/es unknown
- 2009-05-22 US US12/470,521 patent/US8039469B2/en active Active
- 2009-05-23 SA SA109300314A patent/SA109300314B1/ar unknown
- 2009-05-25 TW TW098117318A patent/TW201008949A/zh unknown
- 2009-05-25 PA PA20098828201A patent/PA8828201A1/es unknown
- 2009-05-25 PA PA20098828101A patent/PA8828101A1/es unknown
- 2009-05-25 PE PE2009000724A patent/PE20091943A1/es active IP Right Grant
- 2009-05-25 PE PE2009000725A patent/PE20091957A1/es not_active Application Discontinuation
- 2009-05-25 TW TW098117331A patent/TWI389906B/zh active
- 2009-05-26 AR ARP090101879A patent/AR071909A1/es not_active Application Discontinuation
- 2009-05-26 AR ARP090101878A patent/AR071908A1/es active IP Right Grant
2010
- 2010-10-08 ZA ZA2010/07204A patent/ZA201007204B/en unknown
- 2010-10-21 DO DO2010000315A patent/DOP2010000315A/es unknown
- 2010-10-26 CR CR11757A patent/CR11757A/es unknown
- 2010-11-01 IL IL209061A patent/IL209061A0/en unknown
- 2010-11-01 IL IL209060A patent/IL209060A/en active IP Right Grant
- 2010-11-18 NI NI201000198A patent/NI201000198A/es unknown
- 2010-11-19 CO CO10145581A patent/CO6311070A2/es active IP Right Grant
- 2010-11-22 EC EC2010010624A patent/ECSP10010624A/es unknown
- 2010-11-22 EC EC2010010623A patent/ECSP10010623A/es unknown
- 2010-11-23 MA MA33370A patent/MA32319B1/fr unknown
- 2010-11-23 CU CU20100229A patent/CU23887B1/es active IP Right Grant
2011
- 2011-08-26 US US13/218,571 patent/US8217036B2/en active Active
2012
- 2012-06-06 US US13/490,309 patent/US8445486B2/en active Active
- 2012-12-18 US US13/718,928 patent/US8575159B2/en active Active
2013
- 2013-07-25 US US13/950,584 patent/US8748421B2/en active Active
2014
- 2014-04-23 US US14/259,414 patent/US8859542B2/en active Active
- 2014-09-04 US US14/477,650 patent/US9174963B2/en active Active
2017
- 2017-05-03 CY CY20171100482T patent/CY1118879T1/el unknown
2019
- 2019-04-10 HR HRP20190680TT patent/HRP20190680T1/hr unknown
- 2019-04-16 CY CY20191100421T patent/CY1121699T1/el unknown

Also Published As

Publication number	Publication date
US8039469B2 (en)	2011-10-18
CU23887B1 (es)	2013-04-19
CY1118879T1 (el)	2018-01-10
US20090291079A1 (en)	2009-11-26
AP2010005453A0 (en)	2010-12-31
TW201008949A (en)	2010-03-01
CA2721692C (en)	2014-01-14
HK1203199A1 (en)	2015-10-23
DK2294072T3 (en)	2017-05-15
US20130109670A1 (en)	2013-05-02
AU2009248993B2 (en)	2011-07-07
WO2009143313A1 (en)	2009-11-26
NZ588526A (en)	2012-08-31
PE20091957A1 (es)	2009-12-30
TWI389906B (zh)	2013-03-21
HK1157328A1 (en)	2012-06-29
CR11757A (es)	2010-11-30
NI201000198A (es)	2011-05-09
SI3216793T1 (sl)	2019-06-28
HRP20170637T1 (hr)	2017-06-30
JP2011522802A (ja)	2011-08-04
KR101331341B1 (ko)	2013-11-19
EP2300483A1 (en)	2011-03-30
DOP2010000315A (es)	2010-12-15
SI2294072T1 (sl)	2017-05-31
AU2009248993A1 (en)	2009-11-26
ME01111B (me)	2013-03-20
ECSP10010623A (es)	2010-12-30
US8859542B2 (en)	2014-10-14
AU2009248997A1 (en)	2009-11-26
CO6311070A2 (es)	2011-08-22
PT2294072T (pt)	2017-05-29
HRP20190680T1 (hr)	2019-06-14
US8445486B2 (en)	2013-05-21
AP2010005452A0 (en)	2010-12-31
MA32319B1 (fr)	2011-05-02
ZA201007204B (en)	2011-12-28
JP2011520979A (ja)	2011-07-21
CU20100229A7 (es)	2011-11-15
ECSP10010624A (es)	2010-12-30
US8575159B2 (en)	2013-11-05
LT2294072T (lt)	2017-06-12
US8748421B2 (en)	2014-06-10
PA8828201A1 (es)	2009-12-16
IL209061A0 (en)	2011-01-31
CN102036995A (zh)	2011-04-27
CA2721692A1 (en)	2009-11-26
US9174963B2 (en)	2015-11-03
CL2009001274A1 (es)	2009-10-16
US20150011752A1 (en)	2015-01-08
AU2009248993C1 (en)	2013-10-03
IL209060A0 (en)	2011-01-31
BRPI0912294A2 (pt)	2015-10-20
US20130315865A1 (en)	2013-11-28
PE20091943A1 (es)	2009-12-19
EP2294072B1 (en)	2017-03-29
US20140248239A1 (en)	2014-09-04
AP2775A (en)	2013-09-30
SA109300314B1 (ar)	2012-09-26
KR20110002485A (ko)	2011-01-07
RS58724B1 (sr)	2019-06-28
DK3216793T3 (da)	2019-05-06
AR071908A1 (es)	2010-07-21
US20130005723A1 (en)	2013-01-03
GEP20125589B (en)	2012-07-25
US8217036B2 (en)	2012-07-10
EP3216793B1 (en)	2019-03-27
TW201011010A (en)	2010-03-16
JP4948677B2 (ja)	2012-06-06
AR071909A1 (es)	2010-07-21
EA201071232A1 (ru)	2011-06-30
US20090304692A1 (en)	2009-12-10
IL209060A (en)	2014-05-28
ES2728163T3 (es)	2019-10-22
CN104230831B (zh)	2016-08-24
EA020317B1 (ru)	2014-10-30
HUE043331T2 (hu)	2019-08-28
EP2294072A1 (en)	2011-03-16
RS55960B1 (sr)	2017-09-29
MY155653A (en)	2015-11-13
CN102036995B (zh)	2014-09-17
WO2009143317A1 (en)	2009-11-26
LT3216793T (lt)	2019-05-10
US20110312955A1 (en)	2011-12-22
UA99361C2 (uk)	2012-08-10
ES2625467T3 (es)	2017-07-19
BRPI0912294B8 (pt)	2021-05-25
CL2009001273A1 (es)	2009-11-27
PT3216793T (pt)	2019-05-30
CY1121699T1 (el)	2020-07-31
MX2010012808A (es)	2010-12-21
CN104230831A (zh)	2014-12-24
PA8828101A1 (es)	2009-12-16
TR201906123T4 (tr)	2019-05-21
CA2721710A1 (en)	2009-11-26
EP3216793A1 (en)	2017-09-13
BRPI0912294B1 (pt)	2019-11-12

Publication	Publication Date	Title
HRP20190680T1 (hr)	2019-06-14	Triazinski spojevi kao inhibitori kinaze p13 i mtor
IL206358A0 (en)	2010-12-30	Pyrrolopyrazine kinase inhibitors
IL206818A0 (en)	2010-12-30	Pyrrolopyrazine kinase inhibitors
EP2150255A4 (en)	2011-10-05	CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
ZA200907777B (en)	2010-07-28	Quinoline derivatives as P13 kinase inhibitors
ZA201102423B (en)	2012-09-26	Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP2046333A4 (en)	2010-09-15	THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
ZA201008808B (en)	2011-10-26	Novel phenylpyrazinones as kinase inhibitors
IL213464A0 (en)	2011-07-31	Kinase inhibitor compounds
ZA201101243B (en)	2012-05-30	Macrocyclics pyrimidines as aurora kinase inhibitors
IL209258A0 (en)	2011-01-31	Pyrrolopyridines as kinase inhibitors
EP2382207A4 (en)	2012-09-12	INHIBITORS OF PI3K / MTOR KINASE
IL210573A0 (en)	2011-03-31	Compounds as kinase inhibitors
PL2231642T3 (pl)	2014-04-30	Pirymidyny jako inhibitory kinazy
IL212755A0 (en)	2011-07-31	Pyrazinopyrazines and derivatives as kinase inhibitors
ZA201008878B (en)	2012-02-29	Naphthyridiniones as aurora kinase inhibitors
GB0608823D0 (en)	2006-06-14	Inhibitors of P13 kinase
PL2294072T3 (pl)	2017-08-31	Związki triazynowe jako inhibitory kinazy p13 i mtor
GB0608854D0 (en)	2006-06-14	P13 kinase inhibitors
ZA201004903B (en)	2011-12-28	Pyrrolopyrazine kinase inhibitors
GB0621606D0 (en)	2006-12-06	Inhibitors of p13 kinase